Sarah Jenkins1, Robert Wesolowski2, Margaret E Gatti-Mays3,4. 1. Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA. 2. Division of Medical Oncology, The Ohio State University, Columbus, OH, USA. 3. Division of Medical Oncology, The Ohio State University, Columbus, OH, USA. Margaret.gatti-mays@osumc.edu. 4. Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, OH, USA. Margaret.gatti-mays@osumc.edu.
Abstract
PURPOSE OF REVIEW: To explore the role of the tumor microenvironment (TME) in breast cancer, identify the changes that occur in the TME during breast cancer progression, and explore the possibility of modifying the TME to improve immune checkpoint inhibitor responses. RECENT FINDINGS: Emerging evidence shows the TME may be shaped by internal and external factors. Preclinical data suggests it may be possible to shift the TME to allow for better immune infiltration. In this review, we summarize emerging evidence of changes in the TME and how it can affect prognosis and responses to therapy. We also examine pre-clinical and clinical research aiming at modulating TME to increase proportion of patients who benefit from immune checkpoint inhibitors. The composition of the TME in breast cancer is likely dynamic and may be altered. These changes may lead to more or less responses to immunotherapy.
PURPOSE OF REVIEW: To explore the role of the tumor microenvironment (TME) in breast cancer, identify the changes that occur in the TME during breast cancer progression, and explore the possibility of modifying the TME to improve immune checkpoint inhibitor responses. RECENT FINDINGS: Emerging evidence shows the TME may be shaped by internal and external factors. Preclinical data suggests it may be possible to shift the TME to allow for better immune infiltration. In this review, we summarize emerging evidence of changes in the TME and how it can affect prognosis and responses to therapy. We also examine pre-clinical and clinical research aiming at modulating TME to increase proportion of patients who benefit from immune checkpoint inhibitors. The composition of the TME in breast cancer is likely dynamic and may be altered. These changes may lead to more or less responses to immunotherapy.
Entities:
Keywords:
Breast cancer,; Immune checkpoint inhibitors (ICIs),; Immunotherapy,; Programmed death ligand-1 (PD-L1); Tumor microenvironment (TME),; Tumor-associated macrophages,; Tumor-infiltrating lymphocytes (TIL),
Authors: David Roulois; Helen Loo Yau; Rajat Singhania; Yadong Wang; Arnavaz Danesh; Shu Yi Shen; Han Han; Gangning Liang; Peter A Jones; Trevor J Pugh; Catherine O'Brien; Daniel D De Carvalho Journal: Cell Date: 2015-08-27 Impact factor: 41.582
Authors: Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz Journal: Science Date: 2017-06-08 Impact factor: 47.728
Authors: Hope S Rugo; Jean-Pierre Delord; Seock-Ah Im; Patrick A Ott; Sarina A Piha-Paul; Philippe L Bedard; Jasgit Sachdev; Christophe Le Tourneau; Emilie M J van Brummelen; Andrea Varga; Roberto Salgado; Sherene Loi; Sanatan Saraf; Dina Pietrangelo; Vassiliki Karantza; Antoinette R Tan Journal: Clin Cancer Res Date: 2018-03-20 Impact factor: 12.531
Authors: Margaret E Gatti-Mays; Justin M Balko; Sofia R Gameiro; Harry D Bear; Sangeetha Prabhakaran; Jami Fukui; Mary L Disis; Rita Nanda; James L Gulley; Kevin Kalinsky; Houssein Abdul Sater; Joseph A Sparano; David Cescon; David B Page; Heather McArthur; Sylvia Adams; Elizabeth A Mittendorf Journal: NPJ Breast Cancer Date: 2019-10-29
Authors: Luc Y Dirix; Istvan Takacs; Guy Jerusalem; Petros Nikolinakos; Hendrik-Tobias Arkenau; Andres Forero-Torres; Ralph Boccia; Marc E Lippman; Robert Somer; Martin Smakal; Leisha A Emens; Borys Hrinczenko; William Edenfield; Jayne Gurtler; Anja von Heydebreck; Hans Juergen Grote; Kevin Chin; Erika P Hamilton Journal: Breast Cancer Res Treat Date: 2017-10-23 Impact factor: 4.872
Authors: Qing Chang; Liang Chang; Mo Li; Liwen Fan; Shunchao Bao; Xinyu Wang; Linlin Liu Journal: Am J Cancer Res Date: 2022-09-15 Impact factor: 5.942